These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Musso G; Gambino R; Durazzo M; Biroli G; Carello M; Fagà E; Pacini G; De Michieli F; Rabbione L; Premoli A; Cassader M; Pagano G Hepatology; 2005 Nov; 42(5):1175-83. PubMed ID: 16231364 [TBL] [Abstract][Full Text] [Related]
44. The role of the lipogenic pathway in the development of hepatic steatosis. Postic C; Girard J Diabetes Metab; 2008 Dec; 34(6 Pt 2):643-8. PubMed ID: 19195625 [TBL] [Abstract][Full Text] [Related]
45. Current status of liver disease in Korea: nonalcoholic fatty liver disease. Park SH Korean J Hepatol; 2009 Dec; 15 Suppl 6():S34-9. PubMed ID: 20037278 [TBL] [Abstract][Full Text] [Related]
46. Mechanisms of disease progression in nonalcoholic fatty liver disease. Jou J; Choi SS; Diehl AM Semin Liver Dis; 2008 Nov; 28(4):370-9. PubMed ID: 18956293 [TBL] [Abstract][Full Text] [Related]
47. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. Cong WN; Tao RY; Tian JY; Liu GT; Ye F Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155 [TBL] [Abstract][Full Text] [Related]
48. Lipotoxicity and steatohepatitis in an overfed mouse model for non-alcoholic fatty liver disease. Gaemers IC; Stallen JM; Kunne C; Wallner C; van Werven J; Nederveen A; Lamers WH Biochim Biophys Acta; 2011 Apr; 1812(4):447-58. PubMed ID: 21216282 [TBL] [Abstract][Full Text] [Related]
55. Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications. Tsochatzis EA; Manolakopoulos S; Papatheodoridis GV; Archimandritis AJ Scand J Gastroenterol; 2009; 44(1):6-14. PubMed ID: 18661429 [TBL] [Abstract][Full Text] [Related]
56. Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Baranova A; Gowder SJ; Schlauch K; Elariny H; Collantes R; Afendy A; Ong JP; Goodman Z; Chandhoke V; Younossi ZM Obes Surg; 2006 Sep; 16(9):1118-25. PubMed ID: 16989692 [TBL] [Abstract][Full Text] [Related]
57. Impact of non-alcoholic fatty liver disease on accelerated metabolic complications. Fan JG J Dig Dis; 2008 May; 9(2):63-7. PubMed ID: 18419637 [TBL] [Abstract][Full Text] [Related]
58. Molecular mechanisms of hepatic fibrosis in non-alcoholic steatohepatitis. Rombouts K; Marra F Dig Dis; 2010; 28(1):229-35. PubMed ID: 20460917 [TBL] [Abstract][Full Text] [Related]
59. [Treatment of NASH: nutritional counseling and physical exercise]. Yoneda M; Fujita K; Iwasaki T; Maeyama S; Terauchi Y; Nakajima A Nihon Rinsho; 2006 Jun; 64(6):1139-45. PubMed ID: 16768122 [TBL] [Abstract][Full Text] [Related]
60. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Neuschwander-Tetri BA Hepatology; 2010 Aug; 52(2):774-88. PubMed ID: 20683968 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]